The Superior Detection Rate of Total-body [Ga]Ga-PSMA-11 PET/CT Compared to Short Axial Field-of-view [Ga]Ga-PSMA-11 PET/CT for Early Recurrent Prostate Cancer Patients with PSA < 0.2 ng/mL After Radical Prostatectomy

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2024 Mar 22

PMID 38514483

Authors

Yining Wang

Liang Dong

Haitao Zhao

Lianghua Li

Gang Huang

Wei Xue

Jianjun Liu

Ruohua Chen

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: [Ga]Ga-PSMA PET imaging has been extensively utilized for the detection of biochemical recurrence (BCR) in prostate cancer. However, the detection rate declines to merely 10-40% when PSA levels are < 0.2 ng/mL employing short axial field-of-view (SAFOV) PET. Prior studies exhibited superior detection rates with total-body [Ga]Ga-PSMA-11 PET compared to SAFOV [Ga]Ga-PSMA-11 PET in BCR patients with PSA > 0.2 ng/mL. Nevertheless, the diagnostic utility of total-body [Ga]Ga-PSMA-11 PET for BCR patients when PSA is < 0.2 ng/mL remains unclear. This study aimed to assess whether total-body [Ga]Ga-PSMA-11 PET/CT could improve the detection rate compared to SAFOV [Ga]Ga-PSMA-11 PET/CT in BCR patients with PSA < 0.2 ng/mL.

Methods: Eighty BCR patients with PSA < 0.2 ng/mL underwent total-body [Ga]Ga-PSMA-11 PET/CT. These patients were matched by baseline qualities to another 80 patients who received SAFOV [Ga]Ga-PSMA-11 PET/CT. The detection rates of total-body [Ga]Ga-PSMA-11 PET/CT and SAFOV [Ga]Ga-PSMA-11 PET/CT were compared utilizing a chi-square test and stratified analysis. Image quality of total-body [Ga]Ga-PSMA PET/CT and SAFOV [Ga]Ga-PSMA-11 PET/CT was assessed based on subjective scoring and objective parameters. The objective parameters measured were SUVmax, SUVmean, standard deviation (SD) of SUV, and signal-to-noise ratio (SNR) of liver and gluteus maximus.

Results: The image quality of total-body [Ga]Ga-PSMA PET/CT was superior to that of SAFOV [Ga]Ga-PSMA-11 PET/CT in both early and delayed scans. The detection rate of total-body [Ga]Ga-PSMA PET/CT for BCR patients with PSA < 0.2 ng/mL was significantly higher than that of SAFOV [Ga]Ga-PSMA-11 PET/CT (73.75% vs. 43.75%, P < 0.001). Total-body [Ga]Ga-PSMA PET/CT resulted in noteworthy modifications to the treatment regimen when contrasted with SAFOV [Ga]Ga-PSMA-11 PET/CT.

Conclusions: In BCR patients with PSA < 0.2 ng/mL, total-body [Ga]Ga-PSMA-11 PET/CT not only demonstrated a significantly higher detection rate compared to SAFOV [Ga]Ga-PSMA-11 PET/CT but also led to significant alterations in treatment regimens.

References

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

Isbarn H, Wanner M, Salomon G, Steuber T, Schlomm T, Kollermann J . Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era. BJU Int. 2009; 106(1):37-43. DOI: 10.1111/j.1464-410X.2009.09134.x. View

Huo H, Shen S, He D, Liu B, Yang F . Head-to-head comparison of Ga-PSMA-11 PET/CT and Ga-PSMA-11 PET/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies. Prostate Cancer Prostatic Dis. 2022; 26(1):16-24. DOI: 10.1038/s41391-022-00581-y. View

Alberts I, Prenosil G, Sachpekidis C, Weitzel T, Shi K, Rominger A . Digital versus analogue PET in [Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer: a matched-pair comparison. Eur J Nucl Med Mol Imaging. 2019; 47(3):614-623. DOI: 10.1007/s00259-019-04630-y. View

Van den Broeck T, van den Bergh R, Briers E, Cornford P, Cumberbatch M, Tilki D . Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. Eur Urol Focus. 2019; 6(2):231-234. DOI: 10.1016/j.euf.2019.06.004. View

Hohberg M, Kobe C, Tager P, Hammes J, Schmidt M, Dietlein F . Combined Early and Late [Ga]PSMA-HBED-CC PET Scans Improve Lesion Detectability in Biochemical Recurrence of Prostate Cancer with Low PSA Levels. Mol Imaging Biol. 2018; 21(3):558-566. DOI: 10.1007/s11307-018-1263-2. View

Kunikowska J, Pelka K, Tayara O, Krolicki L . Ga-68-PSMA-11 PET/CT in Patients with Biochemical Recurrence of Prostate Cancer after Primary Treatment with Curative Intent-Impact of Delayed Imaging. J Clin Med. 2022; 11(12). PMC: 9225064. DOI: 10.3390/jcm11123311. View

Lu Y, Wilson Z, Xu G, Xu Z, Pan T, Wei P . Diagnostic Performance of PSMA-Based 18 F-DCFPyL PET/CT in Prostate Cancer Patients After Definitive Treatment With PSA Level ≤0.2 ng/mL. Clin Nucl Med. 2023; 48(12):1021-1027. DOI: 10.1097/RLU.0000000000004893. View

Solomonidou N, Germanou D, Strouthos I, Karagiannis E, Farolfi A, Koerber S . PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml. Eur J Nucl Med Mol Imaging. 2023; 50(8):2529-2536. PMC: 10250454. DOI: 10.1007/s00259-023-06185-5. View

10.

Witkowska-Patena E, Gizewska A, Dziuk M, Misko J, Budzynska A, Walecka-Mazur A . Diagnostic performance of 18F-PSMA-1007 PET/CT in biochemically relapsed patients with prostate cancer with PSA levels ≤ 2.0 ng/ml. Prostate Cancer Prostatic Dis. 2019; 23(2):343-348. DOI: 10.1038/s41391-019-0194-6. View

11.

Zhang X, Cherry S, Xie Z, Shi H, Badawi R, Qi J . Subsecond total-body imaging using ultrasensitive positron emission tomography. Proc Natl Acad Sci U S A. 2020; 117(5):2265-2267. PMC: 7007535. DOI: 10.1073/pnas.1917379117. View

12.

Wang Y, Chen Z, Zhu Y, Zhao H, Li L, Huang G . Total-body [ Ga]Ga-PSMA-11 PET/CT improves detection rate compared with conventional [ Ga]Ga-PSMA-11 PET/CT in patients with biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2023; 50(13):4096-4106. DOI: 10.1007/s00259-023-06355-5. View

13.

Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel F, Hartenbach M . Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. J Nucl Med. 2017; 59(3):469-478. DOI: 10.2967/jnumed.117.198119. View

14.

Mihatsch P, Beissert M, Pomper M, Bley T, Seitz A, Kubler H . Changing Threshold-Based Segmentation Has No Relevant Impact on Semi-Quantification in the Context of Structured Reporting for PSMA-PET/CT. Cancers (Basel). 2022; 14(2). PMC: 8773894. DOI: 10.3390/cancers14020270. View

15.

van Sluis J, Boellaard R, Somasundaram A, van Snick P, Borra R, Dierckx R . Image Quality and Semiquantitative Measurements on the Biograph Vision PET/CT System: Initial Experiences and Comparison with the Biograph mCT. J Nucl Med. 2019; 61(1):129-135. DOI: 10.2967/jnumed.119.227801. View

16.

Calderon E, Schmidt F, Lan W, Castaneda-Vega S, Brendlin A, Trautwein N . Image Quality and Quantitative PET Parameters of Low-Dose [F]FDG PET in a Long Axial Field-of-View PET/CT Scanner. Diagnostics (Basel). 2023; 13(20). PMC: 10606613. DOI: 10.3390/diagnostics13203240. View

17.

Fendler W, Calais J, Eiber M, Flavell R, Mishoe A, Feng F . Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019; 5(6):856-863. PMC: 6567829. DOI: 10.1001/jamaoncol.2019.0096. View

18.

Alberts I, Sachpekidis C, Gourni E, Boxler S, Gross T, Thalmann G . Dynamic patterns of [Ga]Ga-PSMA-11 uptake in recurrent prostate cancer lesions. Eur J Nucl Med Mol Imaging. 2019; 47(1):160-167. DOI: 10.1007/s00259-019-04545-8. View

19.

Badawi R, Shi H, Hu P, Chen S, Xu T, Price P . First Human Imaging Studies with the EXPLORER Total-Body PET Scanner. J Nucl Med. 2019; 60(3):299-303. PMC: 6424228. DOI: 10.2967/jnumed.119.226498. View

20.

Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I . Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and.... Eur Urol. 2019; 77(4):403-417. DOI: 10.1016/j.eururo.2019.01.049. View